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If examination of journal performance is a surrogate for the vitality of a 
discipline, the continued ascension of Clinical Pharmacology and Therapeutics 
(CPT) bodes well for the evolution and practice of human therapeutics in this 
decade. CPT has excelled as the authoritative, cross-disciplinary journal in 
experimental and clinical medicine devoted to publishing advances in the 
nature, action, efficacy and evaluation of therapeutics in humans. Building on a 
foundation that established the core tenets, and a framework providing the 
structural integrity for the field, CPT was conceived by visionary precedent 
editors and editorial teams who were themselves leaders of this discipline.1 
Today, CPT is regarded as the premier international forum for the intersection of 
diverse communities of practice enriching the discovery and application of 
therapeutics in this new era of molecular science and translational medicine 
(Fig. 1).2 
 The vigor of CPT is evidenced by the increased enthusiasm of medical 
and clinical pharmacology communities to publish their work in this peer-
reviewed communication medium. Indeed, CPT is over-subscribed, and 
submissions exceed available space. In 2010, there were a total of ~800 
submissions, with an acceptance rate of ~20% for original research. Similarly, the 
content of CPT is widely disseminated, with more than 2,000,000 page views 
online and 150,000 access events in PubMed last year alone. Dissemination of 
journal content is remarkably facilitated by the evolution of the CPT website and 
its accessibility through the Nature Publishing Group (NPG) counterpart, which 
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sustains over 2 million visits daily. This exposure and access, coupled with the 
high quality of the content and its potential to transform practice within the 
discipline is reflected in the consistently high impact factor calculated by the 
Institute for Scientific Information (ISI), which was 6.96 in 2009. Over the years, the 
sustained impactfulness has continued to position CPT as a top journal primarily 
publishing original research in the ISI category of pharmacology and pharmacy. 
 Beyond the impact of the primary research, CPT continues to strive to 
inform the readership through the evolution of innovative content. 
Commentaries3 and Point-Counterpoint4 shape the science and practice of 
clinical pharmacology by creating a forum for open debate on the most 
pressing and volatile issues in the discipline. Macroscopy attempts to 
contextualize the practice of clinical pharmacology within the larger framework 
of economic, social and political reality impacting our international community 
of practice.5 Discovery probes the cellular and molecular mechanisms 
emerging from enabling platform technologies that provide insight into 
pathophysiology and open new avenues with transformative clinical potential in 
diagnostics and therapeutics.6 Translation explores cutting edge diagnostic and 
therapeutic paradigms emerging from mechanistic insights in pathophysiology 
that bridge discovery science and clinical practice, new tools that optimize 
therapeutic decision-making, novel algorithms from development and clinical 
science that accelerate discovery of targeted interventions, and clinical 
observations that yield unexpected insights into fundamental mechanisms 
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underlying pathophysiology (reverse translation).7 Development highlights 
emerging innovations in tools, platforms, and applications that transform 
diagnostic and therapeutic development, new algorithms that optimize the 
clinical utility of patient- and population-based interventions, and evolution of 
regulatory and economic policies centered on optimizing disease 
management.8, 9 Opinions provide a forum for discussion of key issues central to 
the multidimensional nature of the discipline, including ethics, education, and 
public policy.10 State of the Art reviews continue to be one of the most popular 
and impactful elements in the journal, quantified by citations, providing detailed 
analysis and perspectives of emerging fields and their applications in 
diagnostics, therapeutics, and patient and population management that shape 
our community.11 
 The success of CPT reflects the considerable talents of individuals who 
work collectively to ensure the highest quality, most engaging, and maximally 
informative product is achieved in each issue. The accomplished and talented 
Associate Editors conceive, select, and evolve the scientific and conceptual 
themes. They identify authors for invited contributions, issue those invitations, 
supervise the review process for invited manuscripts, and generate the editorial 
content for each issue. Moreover, they manage the review of all submitted 
manuscripts, performing the initial evaluation to determine suitability for review, 
analyzing those reviews, and preparing decisions on each manuscript. The 
Editorial Board is comprised of leaders in the field who provide context and 
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direction for thematic issues, suggest authors for invited contributions, and 
contribute reviews to each manuscript considered by the journal. The 
Publications Committee of the American Society for Clinical Pharmacology and 
Therapeutics (ASCPT), the owner of CPT, ensures that the journal and its scientific 
leadership are unencumbered by fiscal considerations and policies of the 
Society, so that the scientific/technical content of the journal reflects the best 
available science and practice, and the editorial content reflects best ideas 
without undue influence. Production of each issue is supervised by the 
Managing Editor and her team in the journal office at ASCPT headquarters. 
These professionals perform the arduous task of tracking all manuscripts, authors, 
and editors to ensure that each issue is complete, adheres to rigorous 
production standards, and is produced according to schedule. Finally, we are 
grateful to our NPG colleagues who have provided generous intellectual and 
resource support in the design, production, and continued evolution of the 
journal. The organization, look, and tone of CPT largely reflect the processes in 
design, strategy and focus that leverage the rich history of NPG and its flagship 
journals. 
 CPT is a living entity, continuously adapting to the changing intellectual 
and informational landscape to remain current and relevant to its readership 
and the discipline. The field of human diagnostics and therapeutics is dynamic 
and evolving, and the rate of progress is exponential, entrained by new 
knowledge in health and disease produced by advances in medical and 
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biological sciences. To keep the readership abreast of these rapidly developing 
fields, CPT will increase invitations for the enormously popular State of the Art 
reviews for each issue, to better cover the broadening landscape of clinical 
pharmacology, from molecules to man to populations.12, 13 In addition, starting 
in 2012, the January issue of the journal will be devoted to Therapeutic Reviews, 
to best ensure that the latest innovations are available to our readership in 
patient management across communities of practice representing clinical 
specialties. This annual component will be conceived and assembled by a 
dedicated Therapeutics Review Editor. Also, following on the tradition of 
interacting with national consortia,14 CPT will work with the Pharmacogenomics 
Research Network (PGRN)15-17, the Pharmacogenomics Knowledge Base 
(PharmGKB), and the Clinical Pharmacogenetics Implementation Consortium 
(CPIC) to produce a regular contribution for CPT to disseminate evidence-based 
guidelines on the application of pharmacogenomic knowledge to the 
therapeutic management of patients and populations18. Finally, there is an 
emerging recognition that one key element of the conceptual continuum for 
clinical pharmacology, including discovery, development, regulation and 
utilization, is the conduct and reporting of Clinical Trials. Indeed, clinical trials 
represent the essential bridge translating discovery science into patient-
centered algorithms transforming the delivery of healthcare. In partnership with 
our colleagues at NPG, CPT is launching a concerted initiative to attract 
manuscripts developed from well-conducted, well-reported and impactful 
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clinical trials. This initiative will be supported by the appointment of dedicated 
Clinical Trials Editors. Moreover, a special fast track process that supports 
expedited reviews will be developed specifically for the timely consideration of 
manuscripts describing clinical trials. 
 Thus, Clinical Pharmacology and Therapeutics continues to be the 
leading journal in the field, highlighting the most impactful and transformative 
science underlying innovations in human diagnosis and therapy. The objectives 
going forward are to amplify the vibrancy of the content, enhance the 
excitement of the science, and expand the platform for open debate and 
discussion beyond traditional boundaries delineating our canonical 
communities of practice to engage policy and decision making both nationally 
and internationally. Innovations in content and production will be followed by 
data collection, assessment and evaluation, to develop the evidence base that 
defines the most impactful elements for the readership and discipline. We look 
forward to working with all of you in the continuing evolution of CPT. 
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Figure Legend 
Figure 1. Clinical Pharmacology and Therapeutics covers for the period 2007-
2010 highlight the broad themes of discovery-development-regulation-use 
underlying the state-of-the-art in the principles and practice of human 
therapeutics. 
